• Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer

    来源: Nasdaq GlobeNewswire / 24 10月 2023 08:00:01   America/New_York

    Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced an upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (November 16-18, 2023, Boston, MA).

     Abstract Titles and PresentersPresentation Details
    NXP800NXP800, a novel, small molecule GCN2 kinase activator,
    demonstrates potent single-agent activity in ARID1A and 
    ARID1B-deficient endometrial cancer xenograft models

    Presenter: Ramez N. Eskander

    Division of Gynecologic Oncology,
    Department of Obstetrics, Gynecology and Reproductive Sciences
    University of California San Diego
    La Jolla, CA, USA
    Session Title
    Poster Session A

    Session Type
    Poster

    Session Date / Time
    November 16th, 7:30-9:00 PM

    About Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating its potential to treat platinum resistant, ARID1a-mutated ovarian carcinoma. The FDA granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule SRC/YES1 kinase family (SFK) inhibitor currently in a Phase 1a dose escalation clinical trial.

    Company Contact

    Ron Bentsur
    Chairman, Chief Executive Officer and President 
    201-614-3151
    rbentsur@nuvectis.com

    Media Relations Contact

    Christopher M. Calabrese 
    LifeSci Advisors 
    Tel: 917-680-5608
    ccalabrese@lifesciadvisors.com


    Primary Logo

分享